Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nektar Therapeutics (NASDAQ:NKTR) and PDL BioPharma (NASDAQ:PDLI).
Nektar Therapeutics (NKTR)
Cowen & Co. analyst Chris Shibutani reiterated a Buy rating on Nektar Therapeutics today and set a price target of $86. The company’s shares closed yesterday at $55.96.
According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 10.1% and a 42.9% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Pieris Pharmaceuticals, United Therapeutics, and Mirati Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nektar Therapeutics with a $92.50 average price target, representing a 65.3% upside. In a report issued on July 25, Piper Jaffray also reiterated a Buy rating on the stock with a $125 price target.
.
See today’s analyst top recommended stocks >>
PDL BioPharma (PDLI)
In a report released yesterday, Phil Nadeau from Cowen & Co. reiterated a Hold rating on PDL BioPharma, with a price target of $3. The company’s shares closed yesterday at $2.53.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 12.7% and a 56.0% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Voyager Therapeutics Inc.
PDL BioPharma has an analyst consensus of Hold, with a price target consensus of $3.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
